289 related articles for article (PubMed ID: 23590229)
1. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.
Worodria W; Ssempijja V; Hanrahan C; Ssegonja R; Muhofwa A; Mazapkwe D; Mayanja-Kizza H; Reynolds SJ; Colebunders R; Manabe YC
AIDS; 2018 Sep; 32(15):2141-2149. PubMed ID: 30005014
[TBL] [Abstract][Full Text] [Related]
3. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
4. Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.
Siika AM; Yiannoutsos CT; Wools-Kaloustian KK; Musick BS; Mwangi AW; Diero LO; Kimaiyo SN; Tierney WM; Carter JE
PLoS One; 2013; 8(1):e53022. PubMed ID: 23301015
[TBL] [Abstract][Full Text] [Related]
5. Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study.
Silverman RA; John-Stewart GC; Beck IA; Milne R; Kiptinness C; McGrath CJ; Richardson BA; Chohan B; Sakr SR; Frenkel LM; Chung MH
PLoS One; 2019; 14(10):e0223411. PubMed ID: 31584992
[TBL] [Abstract][Full Text] [Related]
6. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
[TBL] [Abstract][Full Text] [Related]
8. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
[TBL] [Abstract][Full Text] [Related]
9. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
11. Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi.
Brown JP; Ngwira B; Tafatatha T; Crampin AC; French N; Koole O
AIDS Res Ther; 2016; 13():24. PubMed ID: 27398087
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
13. Effects of highly active antiretroviral therapy on the survival of HIV-infected adult patients in urban slums of Kenya.
Muhula SO; Peter M; Sibhatu B; Meshack N; Lennie K
Pan Afr Med J; 2015; 20():63. PubMed ID: 26090021
[TBL] [Abstract][Full Text] [Related]
14. Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study.
Zhao Y; Wu Z; McGoogan JM; Shi CX; Li A; Dou Z; Ma Y; Qin Q; Brookmeyer R; Detels R; Montaner JSG
Clin Infect Dis; 2018 Feb; 66(5):727-734. PubMed ID: 29069362
[TBL] [Abstract][Full Text] [Related]
15. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town.
Kaplan R; Hermans S; Caldwell J; Jennings K; Bekker LG; Wood R
BMC Infect Dis; 2018 Jul; 18(1):356. PubMed ID: 30064368
[TBL] [Abstract][Full Text] [Related]
16. The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study.
Yang CH; Chen KJ; Tsai JJ; Lin YH; Cheng SH; Wang KF; Chiou HY
BMC Infect Dis; 2014 Jun; 14():304. PubMed ID: 24897928
[TBL] [Abstract][Full Text] [Related]
17. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.
Manosuthi W; Chottanapand S; Thongyen S; Chaovavanich A; Sungkanuparph S
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):42-6. PubMed ID: 16885778
[TBL] [Abstract][Full Text] [Related]
18. Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.
Schmaltz CA; Santoro-Lopes G; Lourenço MC; Morgado MG; Velasque Lde S; Rolla VC
PLoS One; 2012; 7(9):e45704. PubMed ID: 23049842
[TBL] [Abstract][Full Text] [Related]
19. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.
Miranda A; Morgan M; Jamal L; Laserson K; Barreira D; Silva G; Santos J; Wells C; Paine P; Garrett D
PLoS One; 2007 Sep; 2(9):e826. PubMed ID: 17786198
[TBL] [Abstract][Full Text] [Related]
20. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
